Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

3.75
+0.31009.01%
Post-market: 3.750.00000.00%17:30 EDT
Volume:726.73K
Turnover:2.62M
Market Cap:312.78M
PE:-2.67
High:3.77
Open:3.45
Low:3.44
Close:3.44
52wk High:5.55
52wk Low:1.03
Shares:83.41M
Float Shares:49.56M
Volume Ratio:1.58
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4029
EPS(LYR):-1.2813
ROE:-179.10%
ROA:-62.95%
PB:27.34
PE(LYR):-2.93

Loading ...

Press Release: Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Dow Jones
·
May 14

Pyxis Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

Creative Global Technology Holdings And 2 Other Promising Penny Stocks

Simply Wall St.
·
May 12

Pyxis Oncology Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 11

Pyxis Oncology appoints Nelson Azoulay chief business officer

Reuters
·
May 08

Pyxis Oncology Initiated at Outperform by Wedbush

Dow Jones
·
May 05

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

TIPRANKS
·
May 05

Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target

MT Newswires Live
·
May 05

Pyxis Oncology Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $6

THOMSON REUTERS
·
May 05

Pyxis Oncology announces annual shareholder meeting notice

Reuters
·
Apr 30

Pyxis Oncology amends 8-K to disclose CEO Lara Sullivan separation agreement

Reuters
·
Apr 30

Pyxis Oncology presents new MICVO preclinical combo data supporting ongoing pembrolizumab trial

Reuters
·
Apr 18

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

GlobeNewswire
·
Apr 18

Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 28

Pyxis Oncology; Director Rachel Humphrey disposes of common shares worth $16,682

Reuters
·
Mar 26

Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 24

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

TIPRANKS
·
Mar 24

Pyxis Oncology price target lowered to $8 from $9 at Stifel

TIPRANKS
·
Mar 24

Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Benzinga Earnings
·
Mar 23

Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million

Reuters
·
Mar 23